Liquidia Corp (NASDAQ: LQDA) CEO Roger Jeffs has finalized the sale of 75,000 shares of common stock, generating roughly $3.44 million in proceeds. The transactions took place over a five-day period between May 8 and May 12, 2026. According to regulatory filings, these sales were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan, which Mr. Jeffs had adopted on November 5, 2025.
Transaction Breakdown
The liquidation occurred in three separate stages, with share prices fluctuating throughout the week:
- May 8, 2026: The first installment involved the sale of 25,000 shares at an average price of $42.1426 per share. During this specific session, individual trade prices ranged from a low of $41.08 to a high of $42.88.
- May 11, 2026: A second block of 25,000 shares was sold at an average price of $41.4961 per share, with the trading range spanning from $40.05 to $44.09.
- May 12, 2026: The final tranche consisted of 25,000 shares sold at an average price of $54.0396 per share, during a period where prices moved between $50.68 and $56.80.
These shares were held indirectly by Mr. Jeffs via Serendipity BioPharma LLC. As a manager of this entity, Mr. Jeffs maintains both voting and dispositive authority over the Liquidia Corp common stock owned by Serendipity BioPharma LLC.
Market Context and Valuation
The timing of these executive sales aligns with a period of significant price strength for Liquidia. The stock has been trading near its 52-week high of $57, with recent prices recorded at $56.59. Over the course of the last year, the company has seen a substantial return of 259%. However, despite this upward momentum, some valuation metrics suggest caution. Analysis indicates that the stock may be trading at levels that exceed its fair value estimate, placing it on lists of highly overvalued companies.
Post-Transaction Holdings
Following these recent sales, Mr. Jeffs continues to maintain a significant stake in the company. He directly holds 1,137,508 shares of Liquidia Corp common stock, an amount that includes various unvested restricted stock units (RSUs) granted during the period from 2023 to 2026. His indirect holdings remain substantial: 46,595 shares are held through the Roger A. Jeffs Living Trust UAD 2/29/2000, where he acts as trustee, and 1,273,095 shares are held indirectly through Serendipity BioPharma LLC.
Financial Performance of Yutrepia
The executive activity follows a period of robust financial results for Liquidia, largely driven by the performance of its drug, Yutrepia. In the first quarter, the company reported revenue of $130 million, which surpassed the consensus expectation of $114 million. Earnings per share also outperformed projections, coming in at $0.52 against an expected $0.35. This success is reflected in Yutrepia's market presence, where it currently holds a 23% market share and has generated net sales of $129.9 million.
Analyst Outlook
Several financial institutions have adjusted their outlooks following the company's recent performance. Jefferies raised its price target to $60, while Raymond James increased its target to $68. H.C. Wainwright set a target of $67, noting that Liquidia has achieved three consecutive quarters of profitability. Other updates include a $62 target from Wells Fargo, which noted strong performance in specific medical markets, and a $59 target from BTIG following the successful launch of Yutrepia.